Every day, articles older than 90 days are removed from the main list and are kept here, organized by topic, with only the title and link to the source. The search and the MielomaAI You may find them too.
Pay attention to old news. Marked as. about 1 year 2 years 5 years 10 years You may also want to check that the information is still up to date: treatments, approvals and prices change quickly. Always confirm with your hematology team.
Access and public health
- FDA approves combination with CELMoD for multiple myeloma that has been previously treated ↗ · The ASCO Post · August 14, 2026
- FDA approves Bristol treatment for multiple myeloma, launching a new class of drugs ↗ · STAT · 14/08/2026
- The U.S. FDA grants accelerated approval to the first CELMoD therapy from Bristol Myers Squibb, in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for patients with multiple myeloma, from the first relapse. ↗ · Business Wire · 13/08/2026
- The U.S. FDA grants accelerated approval to the CELMoD therapy from Bristol Myers Squibb, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for patients with multiple myeloma, from the first relapse. ↗ · Bristol Myers Squibb · August 13, 2026
- FDA approves iberdomide with daratumumab and dexamethasone for relapsed/refractory myeloma ↗ · OncLive · 13/08/2026
- New treatment reduces risk of myeloma progression by 83% and seeks a cure. · CNN Brasil · 24/07/2026
- The U.S. Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s new drug application for Mezigdomide in patients with recurrent or resistant multiple myeloma. ↗ · Business Wire · 13/07/2026
- FDA accepts Bristol-Myers's request for new therapy for multiple myeloma · Economic Value · 13/07/2026
- Johnson & Johnson receives approval from Anvisa for TECVAYLI® (teclistamabe) in combination with DALINVI® (daratumumab) subcutaneous (SC) for relapsed or refractory multiple myeloma, expanding treatment options available for patients ↗ · PR Newswire · 18/06/2026
- CONICT approves inclusion of medication for multiple myeloma in the SUS · JOTA Info · 14/05/2026
- CellCentric announces a Series D funding round of $220 million, with oversubscribed demand, to advance critical trials of Inobrodib in multiple myeloma. ↗ · Business Wire · 06/05/2026
- São Vicente: The Baptist de Sousa Hospital hosts the I Symposium on Multiple Myeloma with approximately 95 participants ↗ · rtc.cv · 24/04/2026
- Health: Clinical Director of Hospital de Sousa warns of an increase in multiple myeloma cases ↗ · asemana.cv · 24/04/2026
- Multiple myeloma in the spotlight: Clinical Director of HBS warns about a concerning increase in cases in Cabo Verde ↗ · News from the North · 24/04/2026
- Clinical director of Hospital de Sousa Baptista warns of an increase in the number of multiple myeloma cases ↗ · Balai Cabo Verde · 24/04/2026
- Hematologists from the Hospital de Sousa strengthen their skills in the treatment of Multiple Myeloma ↗ · rtc.cv · 23/04/2026
- Blenrep from GSK receives regulatory approval in China, amid a doubling in the incidence of multiple myeloma. ↗ · Yahoo Finance UK · 20/04/2026
- The FDA approves combination with teclistamab (Tecvayli) in multiple myeloma in relapse or refractory status. · Oncology News Central · 06/03/2026
- Johnson & Johnson has announced FDA approval in the US of TECVAYLI® in combination with DARZALEX FASPRO® for relapsed/refractory multiple myeloma, offering a potential new standard of care from the second line. ↗ · Johnson & Johnson · 05/03/2026
- Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line · Johnson & Johnson · 05/03/2026
- FDA Approves Teclistamab Plus Subcutaneous Daratumumab for Relapsed/Refractory Multiple Myeloma · OncLive · 05/03/2026
- Public Consultation No. 06/2026 – proposal to incorporate lenalidomide for the treatment of patients with multiple myeloma in the SUS ↗ · Biored Brasil · 23/02/2026
- Two treatments for multiple myeloma approved by the FDA ↗ · Michigan Medicine · 12/02/2026
- FDA approves quadruplet with daratumumab in multiple myeloma without indication for transplant ↗ · Oncology News Central · 28/01/2026
- Four-drug regimen based on DARZALEX and FASPRO® approved in the US for newly diagnosed patients with multiple myeloma who are not eligible for transplant. ↗ · PR Newswire · 27/01/2026
- FDA approves daratumumab and hialuronidase in combination with VRd in multiple myeloma ↗ · The ASCO Post · January 27, 2026
- Innovent announces that the IBI3003 (trispecific monoclonal antibody GPRC5D/BCMA/CD3) has received accelerated access designation from the FDA of the United States for relapsed or refractory multiple myeloma. ↗ · PR Newswire · 26/01/2026
- Arcellx is advancing the conversation on its platform and the importance of early access to CAR T cells for patients with multiple myeloma during the Tandem 2026 meetings. ↗ · Business Wire · 21/01/2026
- Multiple myeloma ↗ · Cambridge University Hospitals · January 15, 2026
- Johnson & Johnson is seeking approval from the EMA for the combination teclistamab–daratumumab. · PharmaTimes · 06/01/2026
- Blenrep: Healthcare plans should cover treatment for multiple myeloma ↗ · Crumbs · 10/12/2025
- FDA approves first treatment for latent multiple myeloma ↗ about 1 year · Oncology News Central · 11/07/2025
- DARZALEX FASPRO® is the first and only treatment approved by the FDA in the US for high-risk latent multiple myeloma ↗ about 1 year · PR Newswire · 11/06/2025
- Blenrep from GSK returns with FDA approval for the third line of multiple myeloma ↗ about 1 year · BioSpace · 24/10/2025
- Blenrep approved by the FDA in the US for multiple myeloma in relapse/refractory status ↗ about 1 year · Business Wire · 10/23/2025
- FDA authorizes the return of the GSK drug for multiple myeloma that had been withdrawn. about 1 year · BioPharma Dive · 10/23/2025
- The FDA has brought Blenrep by GSK back to the market for multiple myeloma ↗ about 1 year · Endpoints News · 10/23/2025
- Blenrep approved by the US FDA for use in the treatment of relapsed/refractory multiple myeloma. about 1 year · GSK · 23/10/2025
- Blenrep approved by the US FDA for use in the treatment of relapsed/refractory multiple myeloma. about 1 year · GSK US · 23/10/2025
- Isatuximab approved for patients with newly diagnosed myeloma ↗ about 1 year · Blood Cancer UK · 24/09/2025
- BH Hospital offers CAR-T cell treatment for patients with multiple myeloma ↗ about 1 year · City Connect · 11/09/2025
- European Commission approves DARZALEX Faspro® for latent multiple myeloma in adults ↗ about 1 year · PR Newswire · 07/23/2025
- FDA delays decision on Blenrep and halts GSK's return to multiple myeloma ↗ about 1 year · Fierce Pharma · 23/07/2025
- GSK provides updates on the FDA advisory committee review of combinations with Blenrep for multiple myeloma in relapse/refractory disease ↗ about 1 year · GSK US · 17/07/2025
- The DREAMM trials by Blenrep at GSK are facing turbulence: the FDA questions the restart in multiple myeloma ↗ about 1 year · BioSpace · 16/07/2025
- NICE approves GSK’s belantamab mafodotin for blood cancer about 1 year · Pharmaceutical Technology · June 16, 2025
- NICE takes a step forward and approves innovative treatment for multiple myeloma ↗ about 1 year · NICE website · 13/06/2025
- Multiple myeloma: Medication authorized in hospital setting ↗ about 1 year · www.netfarma.pt · 30/05/2025
- Multiple myeloma ↗ about 1 year · nhs.uk · 27/05/2025
- The audience assesses the treatment of multiple myeloma in the SUS ↗ about 1 year · Parliament Portal · 23/05/2025
- A multiple myeloma patient treated at the 12 of October Hospital with the first commercially available CAR-T in Spain is disease-free seven months later ↗ about 1 year · Madrid Community | · 24/02/2025
- Approved Darzalex Faspro and Sarclisa for multiple myeloma ↗ about 1 year · National Cancer Institute (.gov) · February 18, 2025
- Approval of Darzalex Faspro and Sarclisa for multiple myeloma ↗ about 1 year · National Cancer Institute (.gov) · 07/01/2025
- New drug for myeloma approved on the NHS for use in line 4 for those who have exhausted their options. 2 years · Blood Cancer UK · 10/10/2024
- The Cavernícola Race Barbadás 2024 event donates part of the registrations to the fight against multiple myeloma ↗ 2 years · Ourense.com · 05/07/2024
- Multiple Myeloma: discussion of treatment within the SUS can impact patients ↗ 2 years · Subscribe to Abril · 17/05/2024
- Counterattack against multiple myeloma: new treatment approved in Brazil ↗ 2 years · Subscribe to Abril · 29/03/2024
- Multiple myeloma: treatment disparity in the SUS versus private system ↗ 3 years · JOTA Info · 11/03/2023
- Special committee discusses treatment of multiple myeloma in the SUS ↗ 3 years · Parliament Portal · 05/10/2023
- FDA lifts partial suspension of Arcellx’s CAR-T CART-ddBCMA trial in multiple myeloma ↗ 3 years · CGTLive® · 15/08/2023
- How to proceed with multiple myeloma treatment in the Brazilian public healthcare system (SUS)? – DrauzioCast #199 ↗ 3 years · Drauzio Varella Portal · 28/07/2023
- The FDA approves TECVAYLI™ (teclistamab), the first bispecific antibody that links T cells, for patients with multiple myeloma in relapse or refractory status. 4 years ago · Johnson & Johnson · 25/10/2022
- The FDA approves teclistamab, a promising new drug for multiple myeloma targeting BCMA and CD3 ↗. 4 years ago · Memorial Sloan Kettering Cancer Center · October 25, 2022
- Darzalex (daratumumab) authorised for use in an inpatient setting ↗ 4 years ago · www.netfarma.pt · 19/04/2022
- Approval of Carvykti becomes the second CAR-T therapy for multiple myeloma ↗ 4 years ago · National Cancer Institute (.gov) · 30/03/2022
- FDA approves BCMA-targeted CAR-T therapy for multiple myeloma ↗ 5 years · National Cancer Institute (.gov) · April 14, 2021
- Multiple Myeloma: The Challenge of Early Diagnosis ↗ 5 years · Public · 09/03/2021
- When should I suspect multiple myeloma? 6 years · NICE CKS · 12/08/2020
- Multiple myeloma ↗ 6 years · NICE CKS · 08/10/2020
- The FDA approves BLENREPTM (belantamab mafodotin-blmf) from GSK for patients with multiple myeloma in relapse or refractory disease. 6 years · GSK US · 05/08/2020
- Multiple myeloma ↗ 6 years · NHS 111 Wales · 08/05/2020
- GSK announces that the European Medicines Agency has accepted the application for belantamab mafodotina for multiple myeloma in relapse or refractory disease. 6 years · GSK · 03/02/2020
- Darzalex from Johnson & Johnson achieves historic approval in the first line for myeloma. 8 years · Fierce Pharma · 08/05/2018
- Modern drug for multiple myeloma gains unprecedented approval ↗ 8 years · Subscribe to Abril · 13/04/2018
- FDA approves new use of lenalidomide in multiple myeloma ↗ 9 years · National Cancer Institute (.gov) · April 18, 2017
- FDA approves new use of lenalidomide in multiple myeloma ↗ 9 years · National Cancer Institute (.gov) · March 16, 2017
- FDA approves new use of daratumumab in multiple myeloma ↗ 9 years · National Cancer Institute (.gov) · 09/12/2016
- Recommendations | Multiple Myeloma: Diagnosis and Treatment | Recommendation ↗ 10 years · NICE website · 10/02/2016
- DARZALEX® (daratumumab) approved by the FDA: the first human monoclonal antibody anti-CD38 available to treat multiple myeloma ↗ 11 years · Johnson & Johnson · November 16, 2015
- FDA approves panobinostat for some patients with multiple myeloma ↗ 11 years · National Cancer Institute (.gov) · March 19, 2015
Patients and associations
- Annual Conference of the APLL focused on the new horizons of multiple myeloma ↗ · My Hematology — search "multiple myeloma" (page 2) · 11/08/2026
- With new treatments, study proposes to change criteria to identify patients with the more severe form of multiple myeloma ↗ · G1 · 26/07/2026
- Second edition of CertamenT: applications close in August ↗ · My Hematology — search "multiple myeloma" (page 2) · 23/07/2026
- Lauren Laverne diagnosed with indolent myeloma ↗ · Blood Cancer UK · 17/07/2026
- CAS approves ‘Burgundy March’ to raise awareness about multiple myeloma · Senate · 01/07/2026
- Medications for myeloma ↗ · Blood Cancer UK · 24/06/2026
- Innovent Biologics announced that the first patient has received the initial dose in a Phase 3 clinical trial of IBI3003 (a tri-specific monoclonal antibody targeting GPRC5D/BCMA/CD3) for the treatment of multiple myeloma. ↗ · PR Newswire · 21/06/2026
- IMS Connect – June 5, 2026 ↗ · International Myeloma Society · June 16, 2026
- Causes of myeloma ↑ · Blood Cancer UK · 13/06/2026
- Margarita Lima's Memorial Days discuss innovation and clinical practice in multiple myeloma ↗ · My Hematology — search "multiple myeloma" (page 3) · 12/06/2026
- Multiple Myeloma: Shedding Light on a Rare, Yet Complex, Blood Disease. ↗ · Pfizer · 09/06/2026
- The new data for TECVAYLI® (teclistamab-cqyv) demonstrates superior PFS and overall survival, already at the first relapse in multiple myeloma. ↗ · PR Newswire · 29/05/2026
- Defining a cure for multiple myeloma: the story of Lu Anna ↗ · Roswell Park Comprehensive Cancer Center · May 28, 2026
- Finding an effective treatment for multiple myeloma: Lu Anna’s story ↗ · Roswell Park Comprehensive Cancer Center · May 28, 2026
- The ELREXFIO from Pfizer significantly improves progression-free survival for patients with relapsed or refractory multiple myeloma after treatment with two classes of drugs. · Business Wire · 28/04/2026
- Multiple myeloma incidence in Cabo Verde is above the world average ↗ · From the Islands · 24/04/2026
- Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma in Study DREAMM-6 Arm B and DREAMM-7 | British Journal of Cancer ↗ · Nature · April 13, 2026
- Multiple myeloma: real-world data exposes bottlenecks in the patient journey ↗ · Future of Health · 30/03/2026
- CLP seminar discusses new therapies and resistance in multiple myeloma ↗ · My Hematology — search "multiple myeloma" (page 3) · 20/03/2026
- The inclusion of a quartet with anti-CD38 is crucial. · My Hematology — search "multiple myeloma" (page 3) · 16/03/2026
- Patients should receive the best therapies first. · My Hematology — search "multiple myeloma" (page 3) · 16/03/2026
- What quadruplet anti-CD38? The new standard for patients newly diagnosed with multiple myeloma ↗ · My Hematology — search "multiple myeloma" (page 3) · 16/03/2026
- Multiple Myeloma: Understanding the Hidden Burdens Beyond the Disease ↗ · Sanofi
- Patients and professionals are discussing the evolution of quality of life in multiple myeloma thanks to therapeutic advances. ↗ · Johnson & Johnson · 09/03/2026
- Multiple myeloma: Understanding the invisible burdens beyond the disease. ↗ · Sanofi
- PET/CT with FDG and new radiopharmaceuticals in patients with multiple myeloma. · www.elsevier.com · 28/01/2026
- Winning Years with Multiple Myeloma: The Advances That Change Everything ↗ · La Provence · 16/12/2025
- Arcellx announces new positive data from the iMMagine-1 study in patients with multiple myeloma in relapse and/or refractory status ↗ · Business Wire · 12/06/2025
- Multiple myeloma: science and innovation expand the chances of living well ↗ · Subscribe to Abril · 12/05/2025
- The impact of research on myeloma ↗ · Blood Cancer UK · 01/12/2025
- Indapta Therapeutics presents clinical activity data from its donor NK cell therapy in patients with multiple myeloma in relapse/refractory status ↗ about 1 year · Business Wire · 11/07/2025
- Commitment to the bulb in a patient with multiple myeloma and secondary peripheral neuropathy ↗ about 1 year · www.elsevier.com · 11/06/2025
- Multiple Myeloma Day ↗ about 1 year · chu-toulouse.fr · 06/11/2025
- Cell therapy brings new hope to patients with multiple myeloma ↗ about 1 year · Roswell Park Comprehensive Cancer Center · September 25, 2025
- Cell therapy brings new hope to patients with multiple myeloma ↗ about 1 year · Roswell Park Comprehensive Cancer Center · September 25, 2025
- What is myeloma? A blood cancer often confused with bone cancer ↗ about 1 year · Blood Cancer UK · 19/09/2025
- Smoldering myeloma ↗ about 1 year · Myeloma UK · 05/09/2025
- 📢 Today is World Multiple Myeloma Day. Did you know that this type of cancer affects the bone marrow cells responsible for producing antibodies? Multiple myeloma is a blood cancer with non-specific symptoms, and easily confused with ↗ about 1 year · Facebook · 05/09/2025
- Multiple myeloma: the story of Michael (video) ↗ about 1 year · BMT InfoNet · 07/08/2025
- Why should transplantation be considered earlier in patients with multiple myeloma? about 1 year · Roswell Park Comprehensive Cancer Center · June 24, 2025
- Immunotherapy increases survival time in multiple myeloma; see ↗ about 1 year · CNN Brasil · 05/06/2025
- Initial results from the Johnson & Johnson tri-specific antibody show promising response in patients with multiple myeloma who have been very pre-treated ↗ about 1 year · PR Newswire · 03/06/2025
- How are researchers at Johnson & Johnson helping people at risk of developing multiple myeloma? about 1 year · Johnson & Johnson · May 14, 2025
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma about 1 year · Business Wire · 14/05/2025
- Coping with myeloma: How do you do it? ↗ about 1 year · Blood Cancer UK · 09/04/2025
- Multiple myeloma and my mental health ↗ about 1 year · Blood Cancer UK · 09/04/2025
- Belantamab mafodotina, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma: updated overall survival and efficacy from the phase 3 DREAMM-7 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Isatuximab, lenalidomide, bortezomib and dexamethasone in the induction of newly diagnosed patients with eligibility for transplant: final analysis of progression-free survival part 1 of the GMMG-HD7 phase 3 trial. about 1 year · International Myeloma Society · January 30, 2025
- Phase 3 Trial IFM2017-03: scheme with less dexamethasone, with daratumumab and lenalidomida, for frail patients with newly diagnosed multiple myeloma ↗ about 1 year · International Myeloma Society · January 30, 2025
- Matthew Wilson Multiple Myeloma Fund ↗ about 1 year · Blood Cancer UK · 12/12/2024
- Study shows that new treatment may delay progression in high-risk latent multiple myeloma ↗ about 1 year · ScienceDaily — Multiple Myeloma · 10/12/2024
- Belantamab mafodotina shows significant benefit in overall survival and reduces the risk of death by 42% in multiple myeloma at first relapse or beyond. about 1 year · GSK US · 09/12/2024
- ASH: with a survival advantage over Darzalex from J&J, GSK strengthens the return of Blenrep in myeloma ↗ about 1 year · Fierce Pharma · 12/09/2024
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition about 1 year · Business Wire · 08/12/2024
- Reinforces the £3 billion plan from GSK: Blenrep shows survival advantage over Darzalex from J&J ↗ 2 years · Fierce Pharma · 14/11/2024
- Much better survival in patients with multiple myeloma over the last decade: results of a Swedish population study ↗ 2 years · National Institutes of Health (NIH) | (.gov) · 24/10/2024
- Stem cell transplant in multiple myeloma: Paul’s story ↗ 2 years · Roswell Park Comprehensive Cancer Center · 05/08/2024
- Multiple myeloma: early detection of aggressive tumors ↗ 2 years · ScienceDaily — Multiple Myeloma · 01/07/2024
- Treatment for relapsed myeloma 2 years · Blood Cancer UK · 15/05/2024
- Treatment goals and types for multiple myeloma ↗ 2 years · Blood Cancer UK · 15/05/2024
- Multiple myeloma: related conditions ↗ 2 years · Blood Cancer UK · 15/05/2024
- What is myeloma? ↗ 2 years · Blood Cancer UK · 15/05/2024
- Symptoms of myeloma ↗ 2 years · Blood Cancer UK · 15/05/2024
- Latent myeloma ↗ 2 years · Blood Cancer UK · 15/05/2024
- First-line treatment for myeloma ↗ 2 years · Blood Cancer UK · 15/05/2024
- Treatment side effects of myeloma ↗ 2 years · Blood Cancer UK · 15/05/2024
- From despair to hope: The Matthew Wilson Fund for Multiple Myeloma ↗ 2 years · Blood Cancer UK · 26/01/2024
- Case of a multiple myeloma patient cured after treating hepatitis reveals that this cancer may be caused by viruses and opens new treatment avenues. 2 years · National Centre for Oncology Research - NCIO · 18/01/2024
- Treatment of Plasma Cell Neoplasms (including Multiple Myeloma) (PDQ®) – Patient Version ↗ 3 years · National Cancer Institute (.gov) · November 17, 2023
- Ask the nurse: myeloma and work ↗ 3 years · Myeloma UK · 09/11/2023
- Diabetes can accelerate the growth of blood cancer, but survival rates vary depending on ethnic origin. 3 years · ScienceDaily — Multiple Myeloma · 29/09/2023
- Dendritic cell vaccine was safe and elicited immune responses in patients with multiple myeloma ↗ 3 years · ScienceDaily — Multiple Myeloma · 22/09/2023
- Symptoms & complications ↗ 3 years · Myeloma UK · 21/09/2023
Multiple myeloma, MGUS and related diseases – a guide for general practitioners 3 years · Myeloma UK · 09/08/2023
- The CAR-T from Clínic-IDIBAPS for multiple myeloma is effective in patients with rising disease ↗ 3 years · Clínic Barcelona · 04/07/2023
- Multiple myeloma: Study on the impact on patients' lives «helps to improve psychosocial adaptation» ↗ 3 years · Just News · 11/03/2023
- Einstein uses CAR-T cells in patients with multiple myeloma ↗ 3 years · Medicine Inc. · 13/12/2022
- Living well with myeloma ↗ 3 years · Blood Cancer UK · 22/11/2022
- Multiple myeloma in patients with systemic lupus erythematosus: two cases 5 years · Scielo.cl · 02/08/2021
- DrauzioCast Special | Multiple Myeloma and the new perspectives for the patient ↗ 5 years · Drauzio Varella Portal · 11/12/2020
- The epigenome of multiple myeloma has been deciphered, with a common molecular characteristic found in patients ↗ 6 years · Clínic Barcelona · 04/09/2020
- Coping with the effects of myeloma ↗ 6 years · Blood Cancer UK · 04/04/2020
- Bone marrow tests showing an increase ↗ 6 years · Blood Cancer UK · 03/04/2020
- Symptoms and diagnosis of myeloma ↗ 6 years · Blood Cancer UK · 31/03/2020
- Multiple myeloma prognosis ↗ 6 years · Blood Cancer UK · 31/03/2020
- Treatment of myeloma and side effects ↗ 6 years · Blood Cancer UK · 30/03/2020
- Multiple Myeloma ↗ 6 years · Blood Cancer UK · 30/03/2020
- March is Multiple Myeloma Awareness Month ↗ 6 years · American Association for Cancer Research (AACR) · 07/02/2020
- Deaths in the Venclexta trial lead AbbVie and Roche to halt patient recruitment with myeloma ↗ 7 years · Fierce Pharma · 19/03/2019
- Survival in myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Living with myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- What is MGUS? ↗ 8 years · Myeloma UK · 16/05/2018
- What causes myeloma? 8 years · Myeloma UK · 16/05/2018
- Treatment of myeloma in relapse ↗ 8 years · Myeloma UK · 16/05/2018
- What is Multiple Myeloma? ↗ 8 years · Myeloma UK · 15/05/2018
- Supportive care treatments ↗ 8 years · Myeloma UK · 14/05/2018
- Multiple myeloma: the story of Maria Dolores ↗ 8 years · Clínica Universidad de Navarra · 23/12/2017
- Multiple myeloma: the story of Ana Maria ↗ 11 years · Universidad de Navarra Clinic · 05/01/2015
- Meeting on the complications of chemotherapy in patients with leukemia, lymphoma and multiple myeloma ↗ for 12 years · Just News · 03/06/2014
- Homepage – Myeloma UK ↗ for 17 years · Myeloma UK · 08/05/2009
Research
- The TECVAYLI® + TALVEY® combination reduced the risk of disease progression or death by 89% and the risk of death by 62% in patients with relapsed/refractory multiple myeloma in the first-line setting. · PR Newswire · 07/23/2026
- The specific combination of J&J reduces the risk of myeloma progression by 89% in a Phase 3 study. ↗ · Fierce Pharma · 23/07/2026
- Bispecific Antibody FcRH5xCD3 cevostamab in recurrent or refractory multiple myeloma: a Phase 1 trial ↗ · Nature · 22/07/2026
- Research that helps people live longer with multiple myeloma. · Canadian Institutes of Health Research · 13/07/2026
- Research to help people with multiple myeloma live longer. · Canadian Institutes of Health Research · 13/07/2026
- Multiple myeloma, the Nantes University Hospital is at the heart of clinical research to advance treatments. ↗ · CHU Media · 08/06/2026
- Significant advances on the front lines and the potential of MRD negativity in multiple myeloma ↗ · My Hematology — search "multiple myeloma" (page 3) · 26/05/2026
- The future of multiple myeloma ↗ · Observer · 22/04/2026
- First results from the first in vivo CAR-T study in multiple myeloma ↗ · The ASCO Post · February 25, 2026
- Pioneering drug candidate shows promise in Phase 1 myeloma study. · Imperial College London · February 23, 2026
- New drug for multiple myeloma shows promise in early study. ↗ · Open Access Government · 23/02/2026
- Regeneron: drug eliminates myeloma cells in a small trial ↗ · Reuters · 10/12/2025
- ASH: anita-cel strengthens the potential to be the best in class while Kite, from Gilead, prepares the launch. · Fierce Biotech · 12/07/2025
- Phase 1 trial of the CAR-T BCMA NEX-T® CC-98633/BMS-986354 therapy in patients with multiple myeloma who have been previously exposed to three classes of drugs ↗ about 1 year · Nature · 05/02/2025
- Phase 2 registration study of anitocabtagene autoleucel in multiple myeloma relapsed and/or refractory: preliminary results from the iMMagine-1 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Phase 3 study of teclistamab with lenalidomide, and teclistamab alone, versus lenalidomide in maintenance after autotransplant in newly diagnosed multiple myeloma: preliminary safety results from the MajesTEC-4/EMN30 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Phase 2 study of inductions with teclistamab in patients newly diagnosed with transplant eligibility: results of the GMMG-HD10/DSMM-XX (MajesTEC-5) trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- First results from the Phase 1 study, the first in humans, with ISB 2001, a triespecific BCMA×CD38×CD3 antibody, in relapsed/refractory multiple myeloma ↗ about 1 year · International Myeloma Society · January 30, 2025
- A new breakthrough in the treatment of multiple myeloma: the promising results of the BENEFIT study. about 1 year · University Hospital of Poitiers Website · 24/01/2025
- ASH 2024: Multiple Myeloma Studies May Change Practice about 1 year · Hematology Advisor · 18/12/2024
- Indapta Therapeutics announces collaboration with Sanofi in a clinical trial for multiple myeloma ↗ about 1 year · Business Wire · 06/12/2024
- Multiple myeloma: cilta-cel proved to be highly effective in a study in real-world clinical practice ↗ 2 years · ScienceDaily — Multiple Myeloma · 10/04/2024
- Efficacy and safety of Isa-KRd induction prior to adapted consolidation based on response in newly diagnosed multiple myeloma with indication for transplant: interim analysis of the IFM2020-02 MIDAS study ↗ 2 years · International Myeloma Society · 27/09/2024
- Blood proteins predict the risk of over 60 diseases ↗ 2 years · ScienceDaily — Multiple Myeloma · 22/07/2024
- Modified plasmacytoid cells show sustained anti-leukemic activity in mice. 2 years · ScienceDaily — Multiple Myeloma · 02/07/2024
- AbbVie initiates Phase 3 trial for multiple myeloma with the experimental drug ABBV-383 ↗ 2 years · PR Newswire · 05/06/2024
- Obesity linked to the detection of a precursor condition for blood cancer ↗ 2 years · ScienceDaily — Multiple Myeloma · 15/01/2024
- Getting precise about multiple myeloma ↗ 2 years · Cancer Research UK - Cancer News · 08/01/2024
- Arcellx announced strong and durable responses of the CART-ddBCMA (anito-cel) regimen in the Phase 1 trial in patients with multiple myeloma in relapse or refractory status. 2 years · PR Newswire · 08/12/2023
- Women who live in neighborhoods easier to walk around have fewer cancers linked to obesity ↗ 3 years · ScienceDaily — Multiple Myeloma · 10/04/2023
- Sequential therapy study in multiple myeloma relapse ↗ 3 years · SciELO Spain · 25/09/2023
- Elranatamab in relapsed or refractory multiple myeloma: results of the MagnetisMM-3 phase 2 trial 3 years · Nature · August 15, 2023
- Multiple myeloma ↗ 3 years · Cancer Research UK - Cancer News · 20/07/2023
- Tecvayli shows promising results in multiple myeloma ↗ 4 years ago · National Cancer Institute (.gov) · 20/10/2022
- New photon counting TAC detects disease better in myeloma ↗ 4 years ago · ScienceDaily — Multiple Myeloma · 06/09/2022
- GSK presents at the ASH 2021 annual meeting the advances of the DREAMM trial program in multiple myeloma. 4 years ago · GSK · 18/11/2021
- Genetics as prognostic and treatment factor in multiple myeloma ↗ 5 years · Scielo.cl · 26/06/2021
- Research into multiple myeloma at Clínic Hospital 6 years · Clínic Barcelona · 22/12/2019
- GSK announces positive top-line results from the pivotal DREAMM-2 study in multiple myeloma ↗ 7 years · GSK · 23/08/2019
- Multiple myeloma research lines ↗ 7 years · Clínic Barcelona · 29/07/2019
- Research on myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Symptoms of myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Research and clinical trials for myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Multiple myeloma ↗ 8 years · Cancer Research UK · 28/06/2018
- ASH: Johnson & Johnson achieves major win with Darzalex in first-line myeloma and reduces risks by half ↗ 8 years · Fierce Pharma · 12/12/2017
- According to a researcher at the Mayo Clinic: the treatment of multiple myeloma ↗ 9 years · Mayo Clinic News Network · 11/06/2017
- The Multiple Myeloma Research Foundation’s focus on drug research has increased ↗ 14 years · Nature · July 10, 2012
Other
- Identifying changes in the bone marrow environment that could open new pathways for treating multiple myeloma. ↗ · Biomedical Research Networking Center (BRIC) · August 18, 2026
- Multiple myeloma: advances that have increased the survival time for this cancer, which is growing among young people ↗ · THE GLOBE · 28/06/2026
- Predicta Biosciences and CIMA LAB Diagnostics have announced a collaboration to develop ultra-sensitive molecular diagnostics based on blood samples for multiple myeloma and other hematological malignancies. ↗ · Business Wire · 06/10/2026
- Pay attention to the crab 🦀. 👇 CRAB is a mnemonic created (a mnemonic term means that it helps to fix). CRAB are symptoms of multiple myeloma cancer. Make sure you understand that multiple myeloma is a cancer, because it might be difficult to associate (it's not a ↗ cancer). · Instagram · May 3, 2026
- Full body MRI is key in the diagnosis and monitoring of multiple myeloma ↗ · Fleury Medicine and Health · 27/04/2026
- Articles about multiple myeloma ↗ · From the Islands · 24/04/2026
- Multiple Myeloma: Addressing Unmet Needs ↗ · Vision · 04/03/2026
- Multiple Myeloma: Conversations about the Invisible – Programs · Observer · 25/02/2026
- Multiple Myeloma: Conversations about the Invisible ↗ · Observer · 23/02/2026
- Project information | MMprofiler to estimate risk in newly diagnosed multiple myeloma | Recommendation ↗ · NICE website · 23/01/2026
- Key Statistics for Multiple Myeloma ↗ · American Cancer Society · January 13, 2026
- Multiple Myeloma: Why Does It Matter to Know About It? ↗ · Renaissance · 30/12/2025
- Multiple myeloma diagnosis following an osteolytic lesion in the jaw ↗ about 1 year · www.elsevier.com · 11/07/2025
- Multiple myeloma ↗ about 1 year · Johnson & Johnson · 22/10/2025
- Taking the lead against multiple myeloma ↗ about 1 year · Johnson & Johnson · September 10, 2025
- IMSS (Mexico) urges early detection of multiple myeloma to prevent complications; 106 cases detected in 2025 ↗ about 1 year · IMSS · 05/09/2025
- Multiple Myeloma: signs, symptoms and causes ↗ about 1 year · The Royal Marsden · 06/12/2025
- What is myeloma? about 1 year · nhs.uk · 27/05/2025
- Causes of myeloma ↗ about 1 year · nhs.uk · 27/05/2025
- Help and support for myeloma ↗ about 1 year · nhs.uk · 27/05/2025
- Symptoms of myeloma ↗ about 1 year · nhs.uk · 27/05/2025
- Tests and next steps in myeloma ↗ about 1 year · nhs.uk · 27/05/2025
- Interview: "It's important to highlight the importance of multiple myeloma diagnosis," José Guilherme Freitas, hematologist ↗ about 1 year · SAPO · 27/05/2025
- Multiple myeloma is treatable, but not curable. Is this about to change? about 1 year · Fred Hutchinson Cancer Center · 03/04/2025
- Frequently Asked Questions about Multiple Myeloma ↗ about 1 year · Madrid Community | · 03/19/2025
- A spotlight on multiple myeloma: the perspective of an expert ↗ about 1 year · Amgen · 03/12/2025
- Project Information | Anitocabtagene autoleucel for Relapsed or Refractory Multiple Myeloma (ID6549) | Recommendation ↗ about 1 year · NICE website · 09/03/2025
- Moving Forward: inspiring change in multiple myeloma ↗ about 1 year · Sanofi
- Is multiple myeloma hereditary? about 1 year · Roswell Park Comprehensive Cancer Center · 04/03/2025
- Is multiple myeloma hereditary? about 1 year · Roswell Park Comprehensive Cancer Center · 04/03/2025
- Is it possible to detect multiple myeloma early? about 1 year · American Cancer Society · February 28, 2025
- What is multiple myeloma? about 1 year · American Cancer Society · February 28, 2025
- Multiple Myeloma: learn more about this silent disease ↗ about 1 year · Renaissance · 20/02/2025
- Multiple myeloma is a type of bone marrow cancer. about 1 year · Madrid Community | · 13/12/2024
- Multiple Myeloma Month 2025 ↗ about 1 year · Johnson & Johnson · 12/12/2024
- Anitocabtagene autoleucel provides deep responses in multiple myeloma in relapse/refractory disease. about 1 year · OncLive · 11/12/2024
- How is multiple myeloma diagnosed? 2 years · Roswell Park Comprehensive Cancer Center · October 30, 2024
- What are the risk factors for multiple myeloma? 2 years · Roswell Park Comprehensive Cancer Center · October 30, 2024
- Multiple myeloma is a little-known cancer in Brazil, affecting more Black people ↗ 2 years · Alma Preta Journalism · 20/10/2024
- Multiple myeloma: learn more about the cancer of Patti Scialfa, Bruce Springsteen’s wife ↗ 2 years · SAPO · 16/10/2024
- Complete molecular profiling of multiple myeloma identifies finer subtypes by copy number and gene expression ↗ 2 years · Nature · August 19, 2024
- Multiple myeloma monitoring increasing ↗ 2 years · Cancer Research UK · 18/07/2024
- Tests for myeloma ↗ 2 years · Cancer Research UK · 10/07/2024
- Multiple myeloma ↗ 2 years · HUG - University Hospitals of Geneva · 29/05/2024
- Summary | Selinexor with bortezomib and dexamethasone in relapsed/refractory multiple myeloma | Recommendation ↗ 2 years · NICE website · 15/05/2024
- New tool assesses the risk of T-cell CAR post-recurrence in multiple myeloma ↗ 2 years · Medscape · 07/03/2024
- Multiple Myeloma: life expectancy has more than doubled ↗ 3 years · Diário de Notícias · 20/09/2023
- Multiple myeloma: increasingly a chronic disease ↗ 3 years · Diário de Notícias · 06/04/2023
- 5 questions about multiple myeloma, with answer ↗ 4 years ago · UT MD Anderson · 27/06/2022
- Liquid biopsy may be able to diagnose and monitor multiple myeloma ↗ 4 years ago · healthonline.pt · 23/06/2022
- It is likely that the incidence of multiple myeloma will increase ↗ 4 years ago · healthonline.pt · 01/04/2022
- Advances in the prognosis of survival for multiple myeloma ↗ 4 years ago · Spanish Cancer Society · 03/31/2022
- Multiple myeloma: hope is becoming increasingly real ↗ 4 years ago · Observador · March 31, 2022
- March burgundy: be aware of the signs of multiple myeloma ↗ 4 years ago · Subscribe to Abril · 28/03/2022
- Multiple Myeloma: increasingly more cases, increasingly more early ↗ 4 years ago · Diário de Notícias · 21/03/2022
- Multiple Myeloma: a silent and little-known disease ↗ 4 years ago · Public · 14/03/2022
- GSK launches Target the Future, a multi-year global program to address myeloma community challenges. 4 years ago · GSK · 12/01/2021
- How can multiple myeloma put a person at risk of catching COVID-19? 5 years · Memorial Sloan Kettering Cancer Center · October 19, 2021
- 9 Questions and Answers about Multiple Myeloma ↗ 5 years · Mayo Clinic Health System · September 30, 2021
- Related conditions ↗ 5 years · Canadian Cancer Society · 04/09/2021
- Multiple myeloma in Chile: clinical characteristics and survival ↗ 5 years · Scielo.cl · 15/07/2021
- Multiple myeloma ↗ 5 years Swiss Medical Review · 06/05/2021
- Survival of people with cancer in mainland France 1989-2018: multiple myeloma and plasmacytoma ↗ 5 years · Public Health France · 16/04/2021
- Multiple myeloma: A rare blood cancer that silently kills (or radically changes lives) ↗ 5 years · View · 07/04/2021
- Multiple myeloma: NINLARO now 100% reimbursed (France) ↗ 5 years · VIDAL · 01/04/2021
- Have you heard of Multiple Myeloma? There's a podcast that explains it ↗ 5 years · Public · 30/03/2021
- Multiple myeloma: a rare blood cancer, silent and with vague symptoms ↗ 5 years · SIC News · March 23, 2021
- Multiple Myeloma: When to Treat and When to Wait ↗ 5 years · UT MD Anderson · 23/11/2020
- Bone disease in multiple myeloma: understanding a little about its pathophysiology ↗ 6 years · Afya | Home · 22/09/2020
- Multiple myeloma diagnosis ↗ 6 years · NICE CKS · 08/10/2020
- Exposure to pesticides increases the risk of myeloma ↗ 6 years · CancerNetwork · 12/06/2020
- Multiple myeloma. A rare, incurable blood cancer that progresses silently ↗ 6 years · News Minute · 20/05/2020
- Multiple myeloma is still an incurable disease ↗ 6 years · Health Atlas · 17/04/2020
- Multiple myeloma: 2020 update on diagnosis, risk stratification and treatment ↗ 6 years · National Institutes of Health (NIH) | (.gov) · March 31, 2020
- Multiple myeloma affects people over the age of 50 and has no cure. Learn how to recognize it ↗ 6 years · TVI · 02/03/2020
- What is myeloma? (multiple myeloma) ↗ 6 years · Macmillan Cancer Support · 27/01/2020
- New drug revives fight against multiple myeloma ↗ 7 years · THE GLOBE · 09/06/2019
- Multiple Myeloma: fatigue and intense bone pain are the main symptoms ↗ 7 years · Health Atlas · 08/04/2019
- Multiple myeloma as a cause of rapidly progressing secondary osteoporosis ↗ 7 years · www.elsevier.com · 29/03/2019
- Multiple myeloma represents 10% of haematological oncology diseases ↗ 7 years · SIC News · 07/03/2019
- Denosumab to prevent bone complications in multiple myeloma (assessment completed) ↗ 7 years · NICE website · 05/12/2018
- Resources and support organizations for myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Referral to a specialist for multiple myeloma symptoms ↗ 8 years · Cancer Research UK · 29/06/2018
- Go to your family doctor if you have symptoms of myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Multiple myeloma screening ↗ 8 years · Cancer Research UK · 29/06/2018
- Coping with myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Treating and preventing myeloma-related problems ↗ 8 years · Cancer Research UK · 29/06/2018
- Types of myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Risks and causes of myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Multiple myeloma stages ↗ 8 years · Cancer Research UK · 29/06/2018
- We need to talk about multiple myeloma ↗ 8 years · Drauzio Varella Portal · 04/04/2018
- Multiple myeloma kills 635 Portuguese people every year ↗ 8 years · RTP · 07/03/2018
- Multiple Myeloma ↗ 9 years · Scientific Journal of Clínica Sagrada Esperança · 14/03/2017
- Summary | Multiple Myeloma: Diagnosis and Treatment | Recommendation ↗ 10 years · NICE website · 10/02/2016
- Multiple myeloma statistics ↗ 11 years · Cancer Research UK · 31/10/2015
- Oncology: over 160 people attended the university hospital to discuss multiple myeloma ↗ 11 years · University Hospital of Poitiers Website · 22/10/2015
- Multiple myeloma incidence statistics are increasing ↗ 11 years · Cancer Research UK · 13/09/2015
- Multiple myeloma mortality statistics are increasing ↗ 11 years · Cancer Research UK · 03/08/2015
- Lymphoma, Leukemia and Multiple Myeloma ↗ 13 years · Atlas of Health · 26/09/2013
- Multiple myeloma ↗ 15 years · The New England Journal of Medicine · March 17, 2011
Treatments
- GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for the treatment of relapsed/refractory multiple myeloma. · PR Newswire · 19/08/2026
- Diagnosis of AL amyloidosis and management of new toxicities in multiple myeloma ↗ · My Hematology — search "multiple myeloma" (page 2) · 07/08/2026
- Focus on: Clinical Update in Oncology ↗ · My Hematology — search "multiple myeloma" (page 2) · 16/07/2026
- Continuous Maintenance Therapy or Fixed Duration Therapy in Multiple Myeloma ↗ · The New England Journal of Medicine · July 15, 2026
- Waiting for CAR-T cells. Gualter's journey to silence multiple myeloma ↗ · Public · 04/07/2026
- The identification of new molecular markers in multiple myeloma is paving the way for more targeted therapies. · Biomedical Research Networking Center (BRIC) · 01/07/2026
- With multiple myeloma, this woman from Brittany, aged 53, recounts her battle in a book. ↗ · West France · 26/06/2026
- Treatment induction based on teclistamab in patients with multiple myeloma who are eligible for transplant and with recent diagnosis: a phase 2 trial. ↗ · Nature · 25/06/2026
- Multiple myeloma: Anvisa expands the use of teclistamabe for the treatment of the disease ↗ · Afya | Home · 06/16/2026
- The new TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hialuronidase-fihj) demonstrate the power of a bispecific combination in relapsed or refractory multiple myeloma at the start of treatment. ↗ · PR Newswire · 06/13/2026
- Subcutaneous medication from Sanofi for multiple myeloma is approved by the European Union. · ICTQ · 12/06/2026
- Immunotherapy reduces by 71% the risk of progression of multiple myeloma in a study conducted in 24 countries ↗ · G1 · 03/06/2026
- Tracking progress, transforming perspectives: the evolution of multiple myeloma treatment. ↗ · Sanofi
- Teclistamab for multiple myeloma in relapse or refractory after one or more treatments (ID6628) ↗ · NICE website · 01/06/2026
- The future for myeloma is bright. · My Hematology — search "multiple myeloma" (page 3) · 26/05/2026
- Emerging Hope in the Multiple Myeloma Market: 7 Therapies in Late-Stage Clinical Trials Approaching the End | DelveInsight ↗ · GlobeNewswire · 25/05/2026
- Gilead completes the acquisition of Arcellx and secures the annuity-cell for myeloma ↗ · Rare Cancer News · 05/05/2026
- Improve how multiple myeloma is understood and treated. ↗ · Mayo Clinic News Network · 04/05/2026
- Belantamab mafodotina with bortezomib and dexamethasone in relapsed/refractory multiple myeloma ↗ · NICE website · 30/04/2026
- Gilead Sciences completes the acquisition of Arcellx ahead of the potential launch of anito-cel ↗ · Business Wire · 28/04/2026
- Opna Bio announces that it has received a fast-track designation for OPN-6602 for the treatment of multiple myeloma. ↗ · Business Wire · 15/04/2026
- Multiple myeloma: understand bone marrow cancer and advances in medicine ↗ · CNN Brasil · 24/03/2026
- Clinic-IDIBAPS optimizes CAR-T academic against multiple myeloma to treat relapses. · Hospital Clínic Barcelona · 20/03/2026
- Linvoseltamab in relapsed or refractory multiple myeloma after three or more prior lines of therapy (ID6609) ↗ · NICE website · 18/03/2026
- Antibody conjugated to BCMA may redefine the treatment of multiple myeloma after the first relapse ↗ · My Hematology — search "multiple myeloma" (page 3) · 13/03/2026
- The submission of TENVAYLI® (teclistamab) as a monotherapy treatment for relapsed/refractory multiple myeloma following at least one prior therapy has been submitted to the EMA. ↗ · Johnson & Johnson · 10/03/2026
- My company produces the medication that helped me fight multiple myeloma. · Johnson & Johnson · 27/02/2026
- Gilead-Arcellx Agreement: Up to $7.8 Billion for Anito CAR-T Cell Therapy in Multiple Myeloma · Oncodaily · 26/02/2026
- Gilead is investing $780 million in multiple myeloma cell therapy with the acquisition of Arcellx. · BioPharma Dive · 23/02/2026
- Gilead acquires Arcellx for $7.8 billion and retains full control of anita-cel ↗ · FirstWord Pharma · 23/02/2026
- Gilead will acquire Arcellx for $7.8 billion and combine its Anktiva with its cancer drugs. · Genetic Engineering and Biotechnology News · February 23, 2026
- Gilead Sciences will acquire Arcellx to maximize the potential of anita-cell. · Business Wire · 23/02/2026
- Belantamab mafodotina with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ↗ · NICE website · 18/02/2026
- Early use of bispecific antibodies in multiple myeloma: current data and open questions · ASCO Daily News · January 29, 2026
- Multiple Myeloma: Improved Prognosis With the Latest Treatments ↗ · Memorial Sloan Kettering Cancer Center · January 27, 2026
- Kelonia Therapeutics announces the FDA approval of the Investigational New Drug (IND) application for KLN-1010, an in vivo CAR-T therapy for relapsed or refractory multiple myeloma. ↗ · Business Wire · 07/01/2026
- Immunotherapy and Personalized Medicine: A Redefinition of Multiple Myeloma Treatment ↗ · News Farma · 16/12/2025
- Anito-cel provides durable answers with controlled safety in multiple myeloma in relapse/refractory patients. · OncLive · 15/12/2025
- Teclistamab with daratumumab in relapsed or refractory multiple myeloma ↗ · The New England Journal of Medicine · 10/12/2025
- ASH 2025: ASH 2025: Arcellx and Gilead’s anti-CD38 CAR-T cell therapy challenges the myeloma market in relapse/refractory disease ↗ · Clinical Trials Arena · 12/09/2025
- Summary | Talquetamab in relapsed and refractory multiple myeloma after 3 or more treatments | Recommendation ↗ · NICE website · 03/12/2025
- First patient enrolled in a new class of treatment for multiple myeloma and diffuse large B-cell lymphoma ↗ · Imperial College London · November 24, 2025
- New cancer drug may help people with multiple myeloma ↗ · Worldwide Cancer Research · 19/11/2025
- Anito-cel emerges as a possible new option in multiple myeloma in relapse/refractory ↗ about 1 year · OncLive · 12/11/2025
- Multiple Myeloma: An Unknown Disease – DrauzioCast #248 ↗ about 1 year · Drauzio Varella Portal · 11/11/2025
- Anito-cel maintains sustained efficacy in multiple myeloma in relapse/refractory patients ↗ about 1 year · CancerNetwork · 30/09/2025
- The hidden switch that causes cancer cells to self-destruct ↗ about 1 year · ScienceDaily — Multiple Myeloma · 09/30/2025
- Isatuximab in combination for multiple myeloma who are not yet treated when a transplant is not possible ↗ about 1 year · NICE website · 24/09/2025
- Treatment turning point in multiple myeloma: towards less chemotherapy? ↗ about 1 year · chu-toulouse.fr · 22/09/2025
- A new experimental CAR-T therapy shows high efficacy in multiple myeloma ↗ about 1 year · Clínic Barcelona · 19/09/2025
- K36 Therapeutics presents clinical update on KTX-1001 for multiple myeloma ↗ about 1 year · PR Newswire · 09/16/2025
- Multiple myeloma is a cancer of plasma cells, a cell that exists in the bone marrow and produces antibodies – immunoglobulins. This malignant cancer leads to the disordered production of a specific type of immunoglobulins. Be aware of the signs. #Saúd ↗ about 1 year · Facebook · 06/09/2025
- Mater Dei will now offer CAR-T treatment for multiple myeloma ↗ about 1 year · Medicine Inc. · 05/09/2025
- Mater Dei innovates in the treatment of multiple myeloma with CAR-T therapy. about 1 year · Health Business · 04/09/2025
- GSK announces extension of the FDA review period for Blenrep (belantamab mafodotina) in relapsed/refractory multiple myeloma. about 1 year · GSK US · 23/07/2025
- Anito-cel provides lasting answers in multiple myeloma in relapse/refractory patients ↗ about 1 year · OncLive · 14/06/2025
- Treatment of myeloma ↗ about 1 year · nhs.uk · 27/05/2025
- Innovative project may reduce treatment costs for multiple myeloma ↗ about 1 year · Medicine Inc. · 27/04/2025
- GSK launches the return of Blenrep to the market with the first combination approval in the UK ↗ about 1 year · Fierce Pharma · 17/04/2025
- Innovative local treatment for osteolytic bone lesions in multiple myeloma ↗ about 1 year · ScienceDaily — Multiple Myeloma · 14/01/2025
- Advances in the treatment of multiple myeloma: diagnosis, symptoms and new therapies ↗ about 1 year · Quirónsalud · 07/01/2025
- Anito-cel shows safety and efficacy in multiple myeloma in relapse/refractory patients ↗ about 1 year · OncLive · 06/01/2025
- Summary | Elranatamab in relapsed and refractory multiple myeloma after 3 or more treatments | Recommendation ↗ about 1 year · NICE website · 11/12/2024
- The safety profile differs from anito-cel (Gilead/Arcellx) compared to Carvykti (J&J/Legend) ↗ about 1 year · BioSpace · 10/12/2024
- DNA can reveal a higher risk of multiple myeloma – and the best treatment ↗ about 1 year · Roswell Park Comprehensive Cancer Center · November 25, 2024
- Summary | Teclistamab in relapsed and refractory multiple myeloma after 3 or more treatments | Recommendation ↗ 2 years · NICE website · 13/11/2024
- ASH: New data from Gilead and Arcellx strengthen its CAR-T approach versus Carvykti in advanced multiple myeloma ↗ 2 years · Fierce Biotech · 11/05/2024
- New technique that makes the competition between tumor cells visible may help to personalize the treatment of multiple myeloma ↗ 2 years · ScienceDaily — Multiple Myeloma · 08/10/2024
- Cell therapy, a new approach in multiple myeloma ↗ 2 years · Bristol Myers Squibb · 10/01/2024
- Safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in clinical practice in multiple myeloma relapsed/refractory: real-world experience with updated follow-up. 2 years · International Myeloma Society · 27/09/2024
- Combination with Blenrep (belantamab mafodotina) receives in China the designation of innovative therapy in multiple myeloma in relapse/refractory ↗ 2 years · GSK · 13/09/2024
- Cancer: New treatment for multiple myeloma arrives in Brazil ↗ 2 years · THE GLOBE · 27/08/2024
- How is multiple myeloma treatment done? 2 years · Cancer Research UK · 07/08/2024
- Blood tests can guide the use of immunotherapy in multiple myeloma ↗ 2 years · ScienceDaily — Multiple Myeloma · 24/07/2024
- Carvykti, from J&J and Legend, shows that CAR-T can prolong life in multiple myeloma ↗ 2 years · Fierce Pharma · 02/07/2024
- From market withdrawal of 3 billion pounds: GSK is aiming high with Blenrep in myeloma ↗ 2 years · Fierce Pharma · 17/06/2024
- Isatuximab, bortezomib, lenalidomide and dexamethasone in multiple myeloma ↗ 2 years · The New England Journal of Medicine · 03/06/2024
- ASCO: After the shine of CAR-T, GSK strengthens the arguments for Blenrep in multiple myeloma ↗ 2 years · Fierce Pharma · 02/06/2024
- Project information | Daratumumab for treating high-risk smouldering multiple myeloma [D10] | Guidance ↗ 2 years · NICE website · 10/04/2024
- Promising drug combination for the treatment of multiple myeloma ↗ 2 years · ScienceDaily — Multiple Myeloma · 25/03/2024
- Ciltacabtagene autoleucel in multiple myeloma after relapse and refractoriness to lenalidomide after 1 to 3 treatments ↗ 2 years · NICE website · 08/03/2024
- New immunotherapy against multiple myeloma shows greater efficacy in the laboratory than CAR-T, which is already in use ↗ 2 years · National Centre for Oncology Research - NCIO · 14/02/2024
- Individual Prediction Model for the Treatment of Multiple Myeloma ↗ 2 years · ScienceDaily — Multiple Myeloma · 09/02/2024
- GSK reveals data on the combination with Blenrep that could revive the drug in multiple myeloma ↗ 2 years · Fierce Pharma · 05/02/2024
- Daratumumab, bortezomib, lenalidomide and dexamethasone in multiple myeloma ↗ 2 years · The New England Journal of Medicine · 12/12/2023
- The discreet Sarclisa from Sanofi achieves an unprecedented victory and points to approval as a first-line treatment for multiple myeloma. 2 years · Fierce Pharma · 12/07/2023
- Summary | Daratumumab with lenalidomide and dexamethasone in the treatment of multiple myeloma who are not treated when transplantation is not possible | Recommendation ↗ 3 years · NICE website · 25/10/2023
- Immunotherapy and the Future of Multiple Myeloma Treatment – DrauzioCast #201 ↗ 3 years · Drauzio Varella Portal · 19/09/2023
- New discoveries to improve the treatment and diagnosis of blood cancer ↗ 3 years · ScienceDaily — Multiple Myeloma · 09/12/2023
- Identified the mechanisms by which multiple myeloma escapes targeted immunotherapy ↗ 3 years · ScienceDaily — Multiple Myeloma · 31/08/2023
- Motexafortide and stem cell transplants in the treatment of multiple myeloma ↗ 3 years · National Cancer Institute (.gov) · 07/07/2023
- Cilt-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma 3 years · The New England Journal of Medicine · 05/06/2023
- Attacking cancer with a nanoparticle containing multiple drugs ↗ 3 years · ScienceDaily — Multiple Myeloma · 26/01/2023
- Gilead enters multiple myeloma cell therapy with the agreement with Arcellx ↗ 3 years · BioPharma Dive · 12/09/2022
- GSK announces new developments regarding the authorization of commercialization of Blenrep (belantamab mafodotin) in the US ↗ 3 years · GSK US · 22/11/2022
- Researchers find treatment options for patients whose cancer returns after CAR-T ↗ 4 years ago · ScienceDaily — Multiple Myeloma · 04/11/2022
- Teclistamab with daratumumab in multiple myeloma in relapse or refractory after one or more treatments (ID6201) ↗ 4 years ago · NICE website · 24/10/2022
- B lymphocytes and plasma cells within the tumor influence early lung cancer and the response to immunotherapy ↗ 4 years ago · ScienceDaily — Multiple Myeloma · 13/09/2022
- Researchers report encouraging immunotherapy option for patients with myeloma in relapse ↗ 4 years ago · ScienceDaily — Multiple Myeloma · 01/09/2022
- Janssen celebrates the first global approval of TECVAYLI® (teclistamab) with European authorization as the first biespecific antibody of its class for multiple myeloma. 4 years ago · Johnson & Johnson · 24/08/2022
- Multiple myeloma: causes, symptoms and treatments ↗ 4 years ago · edge.prnewswire.com · 20/07/2022
- Teclistamab for multiple myeloma in relapse or refractory status ↗ 4 years ago · The New England Journal of Medicine · 05/06/2022
- Fresenius Kabi launches new generic for the treatment of multiple myeloma ↗ 4 years ago · Business Wire · 02/05/2022
- Summary | Daratumumab alone in multiple myeloma in relapse and refractory | Recommendation ↗ 4 years ago · NICE website · 13/04/2022
- Multiple myeloma: from symptoms to treatments ↗ 4 years ago · Public · 25/03/2022
- Daratumumab in combination for multiple myeloma who is not treated when transplant is feasible ↗ 4 years ago · NICE website · 02/02/2022
- Identified a new therapeutic target in multiple myeloma ↗ 4 years ago · Institut Pasteur · 11/01/2022
- Multiple myeloma: find out what it is, what the symptoms are, how diagnosis and treatment occur ↗ 4 years ago · Unifor · 09/12/2021
- Overview | Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | Guidance 5 years · NICE website · 28/04/2021
- Daratumumab subcutaneous: another advancement in the treatment of multiple myeloma ↗ 5 years · Afya | Home · November 30, 2020
- Treatment when myeloma returns (relapse) ↗ 6 years · Cancer Research UK · 17/09/2020
- First myeloma treatment ↗ 6 years · Cancer Research UK · 17/09/2020
- Few relapses 7 years after transplant in multiple myeloma ↗ 6 years · CancerNetwork · 17/06/2020
- Treating multiple myeloma with CAR-T cells, an innovative immunotherapy ↗ 7 years · University Hospital of Poitiers Website · 18/10/2019
- Arcellx raises $85 million to test its BCMA-targeting cell therapy in humans ↗ 7 years · Fierce Biotech · 10/04/2019
- Treatment of multiple myeloma in adults | XPOVIO® (selinexor) ↗ 7 years · XPOVIO · September 15, 2019
- Treatment of Acute Kidney Injury Caused by Multiple Myeloma with High-Flow Polisher Filter | Dialysis and Transplant ↗ 7 years · www.elsevier.com · 08/04/2019
- Breakthrough drug shows early promise for multiple myeloma 8 years · Imperial College London · 08/10/2018
- Genmab announces submission of European approval request for daratumumab in refractory multiple myeloma ↗ 8 years · Genmab · 20/08/2018
- Recovery after a stem cell transplant in myeloma ↗ 8 years · Cancer Research UK · 30/06/2018
- Radiotherapy in myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Treatment options for myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Stem cell transplant in myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Treatment for myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Multiple myeloma: from diagnosis to treatment ↗ 10 years · Royal Australian College of General Practitioners (RACGP) · 18/08/2016
- New targets for the treatment of multiple myeloma ↗ 10 years · FAPESP Agency · 06/04/2016
- Official website for patients | DARZALEX® and DARZALEX FASPRO® (daratumumab) ↗ 11 years · edge.prnewswire.com · 17/11/2015
- Late diagnosis complicates treatment of multiple myeloma ↗ 13 years · Drauzio Varella Portal · 01/04/2013
